Figure S8 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Year: 2023
Type: other
Abstract: Canine primary lung cancer cell line sensitivity to erlotinib. Five canine cell lines (three HER2WT and two HER2V659E) and one human cell line BT474 (HER2amp) were treated with 10 erlotinib doses ranging from 5x10-8 to 50 μM for 72 hours with CellTiterGlo viability endpoints measured and shown as percent growth inhibition relative to DMSO vehicle control.
Authors: Gwendolen Lorch, Karthigayini Sivaprakasam, Victoria Zismann, Nieves Perdigones, Tania Contente-Cuomo, Alexandra Nazareno, Salvatore Facista, Shukmei Wong, Kevin Drenner, Winnie S. Liang, Joseph M. Amann, Sara L. Sinicropi-Yao, Michael J. Koenig, Krista La Perle, Timothy G. Whitsett, Muhammed Murtaza, Jeffrey M. Trent, David P. Carbone, William P.D. Hendricks
Language: English
Topic: Veterinary Oncology Research
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362408400